Children, usually under 4 years; slight female predominance
Fewer than 1 per million children per year
Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.
Clinical Presentation & Hallmark Symptoms
Presenting signs most frequently observed across clinical case series
Genomic Profiling & Defining Molecular Lesions
Critical diagnostic fusions, somatic mutations, and therapeutic targets
Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.
Standard-of-Care Treatment Protocol
Frontline and multimodal strategies established under international consensus guidelines
Maximal safe resection - extent of resection is a strong prognostic factor
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Intensive induction chemotherapy
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
High-dose chemotherapy with stem cell rescue
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Radiotherapy in children old enough to receive it safely
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Clinical trial enrolment wherever available
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Prognosis & Disease Trajectory
Objective clinical outlook without false reassurance
Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.
Active Research, Biomarkers & Clinical Trials
Novel investigational agents, phase I/II trials, and international rare disease consortia
LIN28A/let-7 axis targeting, ALK and IGF1R inhibition, and refined risk-adapted protocols are the principal research directions.
Need Help Matching to an Active Rare Cancer Trial?
ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.
Verified Specialists for Embryonal Tumor with Multilayered Rosettes
Dr. Maryam Fouladi
Co-Director, Pediatric Neuro-Oncology Program
Nationwide Children’s Hospital
Columbus, USA
Dr. Chan Mei Yoke
Senior Consultant, Pediatric Oncology
KK Women’s and Children’s Hospital (KKH)
Singapore, Singapore
Prof. Stefan Pfister
Director, Hopp Children’s Cancer Center
Hopp Children’s Cancer Center / Heidelberg University
Heidelberg, Germany
Dr. Sameer Bakshi
Professor of Medical Oncology
AIIMS, New Delhi
New Delhi, India
Designated Cancer Centers with Dedicated Programs
NCI-Designated Comprehensive Cancer Center
World-leading rare tumor board & pediatric solid tumor protocols
NCI-Designated Comprehensive Cancer Center
Largest specialized rare cancer and sarcoma multidisciplinary program
NCI-Designated Comprehensive Cancer Center
Pioneering genomic molecular tumor boards & rare histologies
NCI-Designated Comprehensive Cancer Center
High-volume surgical oncology & rare endocrine/neuroendocrine expertise
Frequently Asked Clinical Questions
Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options
Related Rare Malignancies in Catalog
Facing a Diagnosis of Embryonal Tumor with Multilayered Rosettes?
Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.